Phase 3 GLOW2 study - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

Representative image of gold bars and tanker traffic in the Strait of Hormuz, illustrating why gold prices climbed to a one-month high even as the waterway was declared completely open.

What gold’s latest rally says about geopolitical hedging after the Strait of Hormuz reopening

Representative image of U.S. Air Force defense data infrastructure and enterprise IT systems, illustrating how Dell Technologies’ EMC contract win could support military test data modernization.

Dell Technologies Inc. (NYSE: DELL): What EMC’s $984.3 m Air Force award means for defense IT strategy

Samsung Galaxy M17 5G review: Is this budget Samsung phone worth buying at ₹15,498?

Samsung Galaxy M17 5G at ₹15,498: Hidden budget beast or just another overhyped Samsung phone?

Representative image of a Boeing C-17 Globemaster III during maintenance, illustrating Boeing’s $166.8 million landing gear spares contract modification and the growing strategic importance of military airlift sustainment.

Why Boeing’s $166.8 m C-17 spares win could matter more than it looks for BA stock

Kodiak Sciences advances Phase 3 GLOW2 study for diabetic retinopathy, evaluating tarcocimab tedromer with extended dosing intervals, aiming for significant patient outcomes.

Read More

Pharma Industry News

Kodiak Sciences advances Phase 3 study of tarcocimab tedromer in diabetic retinopathy

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company focused on developing transformative therapeutics for retinal diseases, announced that…

byPallavi Madhiraju

May 14, 2024

web analytics